Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CD44 | P16070 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1329650 | 0.86 | LMNA (0.46) | KMT2AMEN1LMNAC5AR1GAA | |
| SCHEMBL4417669 | 0.85 | C5AR1 (0.42) | KMT2AMEN1LMNAC5AR1GAA | |
| SCHEMBL1329134 | 0.85 | LMNA (0.44) | KMT2AMEN1LMNAC5AR1GAA | |
| SCHEMBL1327169 | 0.84 | MAOB (0.42) | KMT2AMEN1LMNAPARP2PARP1 | |
| SCHEMBL1327975 | 0.83 | MEN1 (0.48) | KMT2AMEN1LMNAC5AR1KDM4E | |
| SCHEMBL1329410 | 0.82 | C5AR1 (0.54) | KMT2AMEN1LMNAC5AR1ALDH1A1 | |
| SCHEMBL1328209 | 0.81 | C5AR1 (0.43) | KMT2AMEN1LMNAC5AR1GAA | |
| SCHEMBL1327356 | 0.80 | C5AR1 (0.46) | KMT2AMEN1LMNAC5AR1GAA | |
| SCHEMBL2140428 | 0.80 | C5AR1 (0.41) | KMT2AMEN1LMNAC5AR1ALDH1A1 | |
| SCHEMBL1327354 | 0.79 | C5AR1 (0.44) | KMT2AMEN1LMNAC5AR1CD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | KMT2A 3960/4885MEN1 3563/4885LMNA 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.